The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Study Aimed at Better Predicting Large Vessel Vasculitis Relapse

New Study Aimed at Better Predicting Large Vessel Vasculitis Relapse

September 20, 2018 • By Elizabeth Hofheinz, MPH, MEd

  • Tweet
  • Email
Print-Friendly Version / Save PDF
vitstudio / shutterstock.com

vitstudio / shutterstock.com

Imagine telling a patient “You’re in remission!” and finding out it’s not true. The last thing you want to do is get it wrong clinically and put your patient on an emotional rollercoaster.

You Might Also Like
  • New Recommendations Guide Imaging in Large-Vessel Vasculitis
  • Infliximab, Tocilizumab Can Help in Large Vessel Vasculitis
  • Large Vessel Vasculitis Outcome Measures: An Update from OMERACT
Explore This Issue
September 2018

With large vessel vasculitis (LVV) in particular, physicians struggle to be accurate, to determine if indeed the disease has gone away or just gone into hiding.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Peter Grayson, MD, MSc, is head of the Vasculitis Translational Research Program at the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health (NIH) in Bethesda, Md. Dr. Grayson and colleagues published an article in the March 2018 issue of Arthritis & Rheumatology on the use of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) as an imaging biomarker for large vessel vasculitis.1

“Like many rheumatologists,” he says, “I have had a patient with LVV who, according to the bloodwork, was in remission, but in fact was not. Determining whether the disease is still active is easier to do shortly after the initial diagnosis when things are more obvious, but it becomes more difficult over the disease course. Tests, such as the erythrocyte sedimentation rate, are not necessarily reliable to determine disease activity.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“There are fewer clinical trials in LVV [than for] forms of small vessel vasculitis, in part because there are no validated outcome measures of disease activity in LVV. “It’s hard to determine if a therapy is effective when it is simultaneously challenging to figure out if the disease is still active.”

‘FDG-PET was useful in differentiating patients with clinically active LVV from controls (a sensitivity of 85% & a specificity of 83%). However, we also observed that the majority of patients with LVV in clinical remission at the time of imaging had FDG-PET scan findings that looked like ongoing vasculitis.’ —Dr. Grayson

Does Bloodwork = Guesswork?

Dr. Grayson

Dr. Grayson

“There is always the concern with LVV that medications improve the blood markers of inflammation without improving inflammation at the tissue level,” Dr. Grayson says. “In fact, when autopsies have been performed on patients with LVV who died of other causes and were thought to be in clinical remission at the time of death, ongoing active vasculitis is almost always detected in the arteries. So somehow, it appears the treatments for LVV are not getting at the underlying vascular inflammation.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“FDG-PET is traditionally used to detect metabolic activity in cancer cells,” he says. “However, it has been known for years that FDG-PET can also be used to visualize inflammation.”

Pages: 1 2 3 | Single Page

Filed Under: Vasculitis Tagged With: large-vessel vasculitis, relapse, RemissionIssue: September 2018

You Might Also Like:
  • New Recommendations Guide Imaging in Large-Vessel Vasculitis
  • Infliximab, Tocilizumab Can Help in Large Vessel Vasculitis
  • Large Vessel Vasculitis Outcome Measures: An Update from OMERACT
  • Large-Vessel Involvement Is an Independent Risk Factor Predicting GCA Mortality

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)